autologous bone marrow-derived mesenchymal stem cells (Johns Hopkins University)

This investigational autologous cell therapy, developed by Johns Hopkins University, involves the intradiscal injection of mesenchymal stem cells (MSCs) derived from a patient's own bone marrow aspirate concentrate (BMC). The therapy is specifically designed to treat chronic discogenic low back pain and degenerative disc disease. The process involves harvesting bone marrow from the patient's posterior iliac crest, concentrating the MSCs, and injecting the resulting concentrate directly into the affected intervertebral discs. The mechanism of action centers on the ability of MSCs to promote tissue repair, reduce inflammation, and potentially regenerate the disc environment, providing a biological alternative to invasive surgical procedures like spinal fusion or total disc replacement.

Other names

autologous bone marrow concentrateBMCautologous stem cellsintradiscal autologous stem cells